Figure 1



6A1
Absorbance @ 490nm
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.00001
0.0001
0.001
0.01
0.1
1
10
Concentration (ug/ml)

Figure 2a



Absorbance @ 490nm
2.5
2
1.5
1
0.5
0
0.0001
0.001
0.01
0.1
1
10
Concentration (ug/ml)
6A1
R&D anti-IL13 mAb
R&D anti-IL13 poly

Figure 2b



6A1
R&D anti- IL13 mAb
Absorbance @ 490nm
0
0.2
0.4
0.6
0.8
1
0.0001
0.001
0.01
0.1
1
10
100
Concentration (ug/ml)

Figure 3



6A1 + cyno IL13
6A1 + human IL13
R&D anti-hIL13 poly + cyno IL13
R&D anti-hIL13 poly + human IL13
Absorbance @ 570nm
0.6
0.5
0.4
0.3
0.2
0.1
0
0.01
0.1
1
10
Concentration 6A1 (ug/ml)

Figure 4



CHO hIL13 + 6A1
CHO hIL13 + anti-hIL13 poly
Absorbance @ 570nm
0.6
0.5
0.4
0.3
0.2
0.1
0
0.01
0.1
1
10
Antibody concentration (ug/ml)

Figure 5



6A1 + Q130 human IL13
anti-human IL13 poly + Q130 human IL13
Absorbance @ 570nm
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
-0.1
-0.2
0.01
0.1
1
10
Antibody Concentration (ug/ml)

Figure 6



6A1
anti-human IL4 mAb
Absorbance @ 490nm
3.5
3
2.5
2
1.5
1
0.5
0
0.00001
0.0001
0.001
0.01
0.1
1
10
Concentration (ug/ml)

Figure 7



Absorbance @ 570nm
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.01
0.1
1
10
Concentration (ug/ml)
6A1

Figure 8



6A1c + human IL13
6A1c + cyno IL13
Absorbance @ 490nm
2.5
2
1.5
1
0.5
0
0.1
1
10
100
% CHO cell supernatant

Figure 9



L1 + A1
L1 + A2
L1 + A3
L1 + A4
L2 + A1
L2 + A2
L2 + A3
L2 + A4
6A1c
Absorbance @ 490nm
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0.001
0.01
0.1
1
Whole mAb concentration (ug/ml)

Figure 10a.



Absorbance @ 490nm
chimaeric 6A1
L1+A1
L2+A1
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.0001
0.001
0.01
0.1
1
10
100
Concentration of mAb (µg/ml)

Figure 10b.



Absorbance @ 490nm
chimaeric 6A1
L1+A1
L2+A1
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.0001
0.001
0.01
0.1
1
10
100
Concentration of mAb (µg/ml)

Figure 11.



Absorbance @ 490nm
2.5
2
1.5
1
0.5
0
chimaeric 6A1
L1+A1
L2+A1
6A1
0.001
0.01
0.1
1
10
100
% Th2 supernatant

Figure 12a.



chimaeric 6A1
L1+A1
L2+A1
6A1
Absorbance @ 490nm
Concentration of mAb (µg/ml)
2.5
2
1.5
1
0.5
0
0.0001
0,001
0.01
0.1
1
10
100

Figure 12b.



Absorbance @ 490nm
1.2
1
0.8
0.6
0.4
0.2
0
0.0001
0.001
0.01
0.1
1
10
100
Concentration of mAb (µg/ml)
chimaeric 6A1
L1+A1
L2+A1
6A1

Figure 13a.



Absorbance @ 570nm
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
-0.05
0.001
0.01
0.1
1
10
chimaeric 6A1
L1+A1
L2+A1
6A1
Concentration of mAb (µg/ml)

Figure 13b.



Absorbance @ 570nm
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
-0.05
0.001
0.01
0.1
1
10
chimaeric 6A1
L1+A1
L2+A1
6A1
Concentration of mAb (µg/ml)

Figure 13c.



Absorbance @ 570nm
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
-0.05
0.001
0.01
0.1
1
10
chimaeric 6A1
L1+A1
L2+A1
6A1
Concentration of mAb (µg/ml)

Figure 13d.



Absorbance @ 570nm
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.001
0.01
0.1
1
10
chimaeric 6A1
L1+A1
L2+A1
6A1
Concentration of mAb (µg/ml)

Figure 14a.



Absorbance @ 490nm
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.001
0.01
0.1
1
10
100
Concentration of mAb (µg/ml)
chimaeric 6A1
L1+A1
L2+A1
6A1
anti-human IL4 mAb

Figure 14b.



Absorbance @ 490nm
1.2
1
0.8
0.6
0.4
0.2
0
0.001
0.01
0.1
1
10
100
Concentration of mAb (µg/ml)
chimaeric 6A1
L1+A1
L2+A1
Anti-human GM-CSF ab

Figure 14c.



Absorbance @ 570nm
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
chimaeric 6A1
L1+A1
L2+A1
6A1
anti-human IL5 polyclonal ab
0,01
0.1
1
10
100
Concentration of mAb (g/ml)

Figure 15.



Average Absorbance at 490nm
DLLLHLKKLFREGRFN
QFVKDLLLHLKKLFRE
DLLVHLKKLFREG QFN
QFVKDLLVHLKKLFRE
2.5
2.0
1.5
1.0
0.5
0.0
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
Peptide

Figure 16a.



Absorbance @ 450nm
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
KDLLLHLKKLFRSG
DLLLHLKKLFRSG
LLLHLKKLFRSG
LLHLKKLFRSG
LHLKKLFRSG
HLKKLFRSG
LKKLFRSG
KKLFRSG
KLFRSG
LFRSG
FRSG
KDLL
KDLLL
KDLLLH
KDLLLHL
KDLLLHLK
KDLLLHLKK
KDLLLHLKKL
KDLLLHLKKLF
KDLLLHLKKLFR
KDLLLHLKKLFRE
KDLLLHLKKLFRSG

Figure 16b.



3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Absorbance @ 490nm
KDLLVHLKKGLFRSG
DLLVHLKKGLFRSG
LLVHLKKGLFRSG
LVHLKKGLFRSG
VHLKKGLFRSG
HLKKGLFRSG
LKKGLFRSG
KKGLFRSG
KGLFRSG
LFRSG
FRSG
KDLL
KDLLV
KDLLVH
KDLLVHL
KDLLVHLK
KDLLVHLKK
KDLLVHLKKL
KDLLVHLKKLF
KDLLVHLKKLFR
KDLLVHLKKLFRS
KDLLVHLKKLFRSG

Figure 17a



Absorbance @ 490nm
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
QFVKDLLLHLKKLFREGRFN
QFVKDLLLHAKKLFREGRFN
QFVKDLLLHLAKLFREGRFN
QFVKDLLLHLKALFREGRFN
QFVKDLLLHLKKAFREGRFN
QFVKDLLLHLKKLAREGRFN
QFVKDLLLHLKKLFAEGRFN
QFVKDLLLHLKKLFRAGRFN
QFVKDLLLHLKKLFREGRFN

Figure 17b




Absorbance @ 490nm
3.5
3
2.5
2
1.5
1
0.5
0
QFVKDLLLHLKKLFREGRFN
QFVKDLLLHAKKLFREGRFN
QFVKDLLLHLAKLFREGRFN
QFVKDLLLHLKALFREGRFN
QFVKDLLLHLKKAFREGRFN
QFVKDLLLHLKKLAREGRFN
QFVKDLLLHLKKLFAEGRFN
QFVKDLLLHLKKLFRAGRFN
QFVKDLLLHLKKLFREGRFN

Figure 17c


Absorbance @ 490nm
QFVKDLLLHLKKLFREGRFN
QFVKDLLLHLAKLFREGRFN
QFVKDLLLHLKALFREGRFN
QFVKDLLLHLKKAFREGRFN
QFVKDLLLHLKKLAREGRFN
QFVKDLLLHLKKLFAEGRFN
QFVKDLLLHLKKLFREGRFN
3.5
3
2.5
2
1.5
1
0.5
0
0.0001
0.001
0.01
0.1
1
10
100
Concentration of mAb (ug/ml)